# Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

> **NCT01949545** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 46 (actual)

## Conditions studied

- Solid Tumors
- Hematologic Malignancies
- Hepatic Impairment

## Interventions

- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT01949545
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-08
- **Final completion:** 2015-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01949545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01949545, "Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01949545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*